• 2020
• Book

Remote Work Revolution: Succeeding from Anywhere

The rapid and unprecedented changes brought on by Covid-19 have accelerated the transition to remote working, requiring the wholesale migration of nearly entire companies to virtual work in just weeks, leaving managers and employees scrambling to adjust. This massive transition has forced companies to rapidly advance their digital footprint, using cloud, storage, cybersecurity, and device tools to accommodate their new remote workforce. Experiencing the benefits of remote working—including nonexistent commute times, lower operational costs, and a larger pool of global job applicants—many companies, including Twitter and Google, plan to permanently incorporate remote days or give employees the option to work from home full-time. But virtual work has it challenges. Employees feel lost, isolated, out of sync, and out of sight. They want to know how to build trust, maintain connections without in-person interactions, and a proper work/life balance. Managers want to know how to lead virtually, how to keep their teams motivated, what digital tools they’ll need, and how to keep employees productive. Providing compelling, evidence-based answers to these and other pressing issues, Remote Work Revolution is essential for navigating the enduring challenges teams and managers face. Filled with specific actionable steps, original illustrations and interactive tools, this timely book will help team members deliver results previously out of reach. Following Neeley’s advice, employees will be able to break through routine norms to successfully use remote work to benefit themselves, their groups, and ultimately their organizations.

• 2020
• Book Chapter

Reflections on comparing India and China

• 2020
• Working Paper

Tamoxifen: Case Histories of Significant Medical Advances

Tamoxifen is considered a “gold standard” treatment for millions of breast cancer patients. In 1985, twelve years after Imperial Chemical Industries (ICI), had first introduced tamoxifen in the United Kingdom (UK), the World Health Organization (WHO) designated it an essential cancer drug. In 2003, V. Craig Jordan, a leading tamoxifen researcher, estimated that “over 400,000 women are alive as a result of tamoxifen therapy.”